Helise Bichefsky, DO
Internal Medicine · West Chester, PANPI 1770533267
Payments from drug & device makers
Across 234 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$426
- Indivior Inc.$349
- Corium, LLC$285
- Braeburn Inc.$231
- Otsuka America Pharmaceutical, Inc.$201
- plus $1K from 26 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$3,90899%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,170 |
| AstraZeneca | 26 | $426 |
| Indivior Inc. | 24 | $349 |
| Corium, LLC | 14 | $285 |
| Braeburn Inc. | 10 | $231 |
| Otsuka America Pharmaceutical, Inc. | 13 | $201 |
| Bausch Health US, LLC | 8 | $136 |
| Alkermes, Inc. | 7 | $124 |
| Axsome Therapeutics, Inc. | 4 | $118 |
| Pfizer | 5 | $102 |
| Lilly USA, LLC | 5 | $101 |
| Orexo US, Inc. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Novo Nordisk | 4 | $66 |
| Almatica Pharma LLC | 3 | $59 |
| Lundbeck LLC | 3 | $53 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Vertex | 1 | $19 |
| Linus Health, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Gilead | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Biogen | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $12 |
How this compares
$3,932 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VivitrolNaltrexone Microspheres | 23 | $33,523 |
| OzempicSemaglutide | 15 | $22,495 |
| JanuviaSitagliptin Phosphate | 21 | $21,526 |
| JardianceEmpagliflozin | 21 | $17,867 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 89 | $8,858 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,915 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,532 |
| Lisdexamfetamine Dimesylate | 23 | $5,263 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $3,030 |
| Atorvastatin Calcium | 165 | $1,753 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,369 |
| SynthroidLevothyroxine Sodium | 16 | $859 |
| Bupropion XlBupropion Hcl | 26 | $854 |
| Rosuvastatin Calcium | 51 | $837 |
| Omeprazole | 31 | $689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Vivitrol | $124 | $33,52323 claims |
| Novo NordiskOzempic | $66 | $22,49515 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $69 | $7,53220 claims |
| Indivior Inc.Suboxone | $349 | $3,03019 claims |
| AbbVieSynthroid | $1,170 | $85916 claims |
| Almatica Pharma LLCSertraline Hcl | $59 | $51061 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $48657 claims |
| Lilly USA, LLCOlanzapine | $101 | $36014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in West Chester
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.